Answers are grounded in this paper and cite their sources.
This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality of life.
No takes yet. Share an insight, caveat, or question.
Tannock et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: